Drugmakers’ Pricing Power Remains Strong
Price increases continue despite pushback from insurers, U.S. lawmakers
Pharmaceutical companies’ power to raise prices is firmly intact despite pushback from health insurers, scrutiny by U.S. lawmakers and anxiety about rising prescription drug spending.
More than two-thirds of the 20 largestpharmaceutical companies said price increases boosted sales of some or most of their biggest products in the first quarter, according to a Wall Street Journal review of corporate filings and conference-call transcripts. Read more here.
Home / Regulatory Policy Left / Drugmakers’ Pricing Power Remains Strong